AMR Sept Banner

ASM Attends UN General Assembly

ASM President, Susan Sharp, Ph.D., joined global leaders at the United Nations General Assembly in New York today in a historical meeting to focus on the commitment to fight AMR.
Read

UN General Assembly Focuses on AMR

Leaders at the UN General Assembly draft a plan for coordinated, cross-cutting efforts to improve the current state of AMR.
Read

Superbugs are a 'Fundamental Threat'

If antibiotics were telephones, we would still be calling each other using clunky rotary dials and copper lines," Stefano Bertuzzi, CEO of ASM, told NBC News.
Read
Become a member today!
JOIN ASM
Submit Abstracts for Biothreats 2017
SUBMIT
Antibacterial Development Conference
REGISTER

Researchers Model Fetal-To-Adult Hemoglobin Switching: Important Step Towards Cure For Blood Diseases

Researchers have engineered mice that model the switch from fetal to adult hemoglobin, an important step towards curing genetic blood diseases such as sickle cell anemia and beta-thalassemia. The research is published in the February 2011 issue of the journal Molecular and Cellular Biology.

 

They also produced for the first time a mouse that synthesizes a distinct fetal-stage hemoglobin, which was necessary for modeling human hemoglobin disorders. These diseases manifest as misshapen hemoglobin, causing anemia, which can be severe, as well as other symptoms, which can range from minor to life-threatening. The cure would lie in causing the body to revert to use of fetal hemoglobin.

 

“The motivation for our research is to understand the basic mechanisms of gene regulation in order to cure human disease,” says Thomas Ryan of the University of Alabama Birmingham, who led the research. “If we can figure out how to turn the fetal hemoglobin back on, or keep it from switching off, that would cure these diseases.”

 

The new model “mimics precisely the timing in humans, completing the switch after birth,” says Ryan. “The previous models didn’t do that.” In earlier models, researchers inserted transgenes, large chunks of DNA containing the relevant genes, randomly into the mouse chromosome. In the new model, the investigators removed the adult mouse globin genes, and inserted the human fetal and adult genes in their places.

 

The successful engineering of a mouse with a fetal-stage hemoglobin means that humanized mouse models with mutant human genes will not die in utero.

 

While the basic principals behind the research are simple, the details are complex. For example, Ryan and Sean C. McConnell, a doctoral student who is the paper’s first author, had to deal with the fact that hemoglobin switching occurs twice in H. sapiens, from embryonic to fetal globin chains in early fetal life, and then to adult globin chains at birth, while wild type mice have a single switch from embryonic to adult chains early in fetal life. “Instead of the single hemoglobin switch that occurs in wild type mice, our humanized knock-in mice now have two hemoglobin switches, just like humans, from embryonic to fetal in early fetal life, and then fetal to adult at birth,” says Ryan.

 

Hemoglobin switching is believed to have evolved to enable efficient transfer of oxygen from the mother’s hemoglobin to the higher oxygen affinity fetal hemoglobin in the placenta during fetal life.

 

(S.C. McConnell, Y. Huo, S. Liu, and T.M. Ryan, 2011. Human globin knock-in mice complete fetal-to-adult hemoglobin switching in postnatal development. Mol. Cell. Biol. 31:876-883.)

TPL_asm2013_SEARCH

8457